Generic Name and Formulations:
In vitro test; fetal fibronectin enzyme immunoassay.
Indications for FULLTERM:
Aid in assessing risk of preterm delivery in ≤7 or ≤14 days from the time of cervicovaginal sample collection in women with signs/symptoms of early preterm labor, intact amniotic membranes, and minimal cervical dilation (<3cm), sampled between ≥24 weeks and <35 weeks gestation. Aid in assessing risk of preterm delivery in <35 weeks during routine prenatal visit between 22 weeks and <31 weeks gestation in women with singleton gestation.
See literature. Not for women with advanced cervical dilatation, ruptured amniotic membranes, cervical cerclage, moderate or gross vaginal bleeding. Collect vaginal sample before any activities that may disrupt cervix (eg, coitus, cervical examinations, vaginal ultrasound, pap smear).
Lubricants, soaps, disinfectants may interfere with test results.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy